Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib vs pemetrexed + platinum in first-line ALK-positive advanced non-squamous NSCLC
CTR20132961Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Apr 2015; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20132961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132961.